<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Fidelity Aberdeen Street Trust - Advisor Sustainable Target Date 2040 Fund — News on 6ix</title>
    <link>https://6ix.com/company/fidelity-aberdeen-street-trust-advisor-sustainable-target-date-2040-fund</link>
    <description>Latest news and press releases for Fidelity Aberdeen Street Trust - Advisor Sustainable Target Date 2040 Fund on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 22 Apr 2026 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/fidelity-aberdeen-street-trust-advisor-sustainable-target-date-2040-fund" rel="self" type="application/rss+xml" />
    <item>
      <title>Immutep Announces Abstract Accepted for Presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting</title>
      <link>https://6ix.com/company/fidelity-aberdeen-street-trust-advisor-sustainable-target-date-2040-fund/news/immutep-announces-abstract-accepted-for-presentation-at-the-american-society-of-clinical-oncology-asco-2026-annual-meeting-2</link>
      <guid isPermaLink="true">https://6ix.com/company/fidelity-aberdeen-street-trust-advisor-sustainable-target-date-2040-fund/news/immutep-announces-abstract-accepted-for-presentation-at-the-american-society-of-clinical-oncology-asco-2026-annual-meeting-2</guid>
      <pubDate>Wed, 22 Apr 2026 04:00:00 GMT</pubDate>
      <description>SYDNEY, AUSTRALIA, April 22, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage immunotherapy</description>
    </item>
  </channel>
</rss>